GlassScriptPhysician profile
Deborah Duan
NPI 1801451885
$12,814.67
in general payments reported to CMS, 2019-2025
22 companies · $3,269 in 2025
The $3,269 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $294 · 2021: $1,696 · 2022: $1,937 · 2023: $3,324 · 2024: $1,110 · 2025: $3,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,800 · Food and Beverage: $3,709 · Entertainment: $189 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,800.00 |
| Food and Beverage | $3,709.01 |
| Entertainment | $188.67 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $5,240.90 | 2023-2025 | Vyzulta, Lotemax, Miebo |
| Alcon Vision LLC | $1,602.49 | 2022-2025 | Total30, Clareon, Tryptyr |
| Sun Pharmaceutical Industries INC. | $647.89 | 2021-2024 | |
| Ivantis, INC | $518.73 | 2021 | |
| Allergan, INC. | $506.14 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $489.75 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $464.58 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $436.35 | 2019-2021 | |
| Coopervision INC. | $392.69 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Oyster Point Pharma, INC. | $359.01 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $333.97 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $291.70 | 2021-2022 | |
| Optos, INC. | $290.31 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $245.01 | 2022 | |
| Abbvie INC. | $211.68 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $196.24 | 2019-2021 | |
| Sight Sciences, INC. | $148.43 | 2022 | |
| Mallinckrodt Hospital Products INC. | $146.18 | 2024 | Acthar |
| Carl Zeiss Meditec, INC. | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Biotissue Holdings INC. | $27.02 | 2022 | |
| Thea Pharma INC. | $15.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Duan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.